ThePeptide.expert
This information is for research and educational purposes only. This is not medical advice.
← All profiles
RUO onlyMetabolic

GLP-3

Triple-Action Metabolic Compound (RT formulation)

A triple-action metabolic research compound combining GLP-1, GLP-2, and GLP-3 receptor activity. Studied for metabolic regulation, gut health, and appetite modulation in preclinical models.

Evidence
Limited human data
Routes
injectable
Available since
Emerging research compound. Available for research use from approximately 2024 onward.

Mechanism of action

Activates multiple glucagon-like peptide receptors simultaneously. GLP-1 receptor activation drives insulin secretion and appetite suppression. GLP-2 receptor activation supports intestinal repair and gut barrier function. Combined receptor activity may produce synergistic metabolic effects beyond single-receptor GLP-1 analogues like semaglutide.

Effects in the body

GLP-3 research targets the metabolic system through multiple simultaneous pathways — appetite regulation, insulin sensitivity, and gut health — potentially addressing metabolic dysfunction more comprehensively than single-target GLP-1 drugs. Research is at an early stage.

Pros & cons (from the literature)

Pros
  • Multi-receptor action may produce broader metabolic effects than single GLP-1 drugs
  • Gut repair properties from GLP-2 receptor activity
  • Early research suggests appetite modulation
  • May complement existing GLP-1 protocols
  • Novel mechanism with limited competition in research space
Cautions
  • Very limited human clinical data available
  • RUO status — not approved or compoundable in USA
  • Multi-receptor activity makes side effect profile harder to predict
  • No established human dosing protocol
  • Significantly less researched than semaglutide or tirzepatide

Protocol summary (from published research)

Research protocols vary significantly. Early animal studies use weight-based dosing. No established human protocol. Extreme caution warranted given limited safety data.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Research Use Only (RUO). Not FDA-approved. Not compoundable by licensed US pharmacies. Early-stage research compound. Available through RUO research suppliers only.

Evidence base

Preclinical animal data only as of 2026. Mechanistically interesting but significantly behind GLP-1 class drugs in clinical validation. Early-stage research compound.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Pro member exclusive

Significant savings on research-grade peptides at a licensed, quality-controlled supplier

Your Pro membership includes an exclusive discount code for 99%+ purity verified research peptides at the best available price, from a licensed supplier we have evaluated for purity standards and compliance. Plus curated guides so you know exactly what to research.

  • • Exclusive discount code included with Pro membership
  • • Curated guide for this specific peptide
  • • Verified 99%+ purity compounds
  • • Removes the guesswork entirely
Upgrade to Pro — $15/month

Cancel anytime · No long-term commitment

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.